|
Dr. Eissenstat, Vice President, Chemistry, has more than 20 years experience as a medicinal chemist, both in the pharmaceutical industry and in government. He received his Ph.D. in organic chemistry at Harvard University. After post-doctoral training at the University of Pittsburgh, Dr. Eissenstat joined Sterling Winthrop Pharmaceuticals as a Senior Research Chemist. Most of the early part of his career was devoted to analgesics research. He was a co-project leader and led the discovery of a unique series of potent cannabinoid agonists and a cannabinoid antagonist. In 1995 Dr. Eissenstat joined the Structural Biochemistry Program at NCI-Frederick as the Head of Medicinal Chemistry. He directed research efforts to discover inhibitors with potential utility for treating AIDS, cancer and malaria. In 1999, Dr. Eissenstat assumed the duties of Acting Director of the Structural Biochemistry Program. In 2000, Dr. Eissenstat joined Tibotec as the Associate Director of the U.S. operation. There, his chemistry group synthesized small molecule HIV fusion inhibitors and enzymatic inhibitors of tuberculosis. Dr. Eissenstat also assisted in the development of potent HIV protease inhibitor, TMC-114, that is now JNJ's Prezista (R). | 